Skip to main content
All lobbying filings

Artemis Policy Group LLC

Artemis Policy Group LLC filed a Q1 report for National Bleeding Disorder Foundation (FKA National Hemophilia Foundation) on April 21, 2025, reporting $50,000 in lobbying income.

Lobbying for National Bleeding Disorder Foundation (FKA National Hemophilia Foundation) · Nonprofit supporting patients with inheritable bleeding disorders.

As filed: ARTEMIS POLICY GROUP LLC for NATIONAL BLEEDING DISORDER FOUNDATION (FKA NATIONAL HEMOPHILIA FOUNDATION).

All filings by Artemis Policy Group LLC · Everything National Bleeding Disorder Foundation (FKA National Hemophilia Foundation) has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 21, 2025
Income
$50,000
What the client paid this registrant for the period.
Client based in
New York

Official filing document

 Lobbyists on this filing 2
  • JOHANNA GRAY
    Previously held: Intern, Senator Barack Obama
  • LESLIE BRADY
    Previously held: Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 6

Reimbursement for hemophilia services and treatments in Medicare Reimbursement for hemophilia services and treatments in Medicaid Issues related to 1115 Waivers in Medicaid Preserving and expanding access to Medicaid

Blood and plasma safety and awareness Bleeding disorders awareness

Implementation of the Affordable Care Act The HELP Copays Act (HR 864) Coverage of hemophilia treatments and services in private insurance plans, including the alternative funding model Policies related to copay accumulator adjustor and maximizer programs Policies related to PBM regulation Healthcare Affordability Act of 2024 (H.R. 9774 / S. 5194) Policies related to the extension of enhanced advanced premium tax credits Protect patients from substandard and junk insurance products House Ways and Means Committee Request for Information - Tax Priorities Patient Protection and Affordable Care Act; HHS Proposed Marketplace Integrity and Affordability Rule (CMS-9884-P)

Funding for federal hemophilia programs in FY25 House and Senate Labor-HHS Appropriations bills NIH FY25 appropriations

Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program

Hemophilia research, prevention, surveillance and service programs and issues Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (H.R. 1796/S. 735)

 Bills named in this filing 5
  • H.R. 864
    Freedom to Cooperate Act
  • H.R. 9774
    Health Care Affordability Act of 2024
  • S. 5194
    Health Care Affordability Act of 2024
  • H.R. 1796
    Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
  • S. 735
    Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem